The Global Collagen and HA-Based Biomaterials Market is Forecast to Reach US$4.6 Billion by 2020
Rising Use of Biomaterials in Regenerative Medicine Drives
the Collagen and HA-Based Biomaterials Market, According to a New Report by Global Industry Analysts, Inc.
GIA announces
the release of a comprehensive global report on Collagen and HA-based
Biomaterials. The
global Collagen and HA-Based Biomaterials market is forecast to reach US$4.6
billion by 2020, driven by the rising use of biomaterials in regenerative
medicine.
Biomaterials
are of vital importance in the medical sector. They are of enormous use and
value in the development of synthetic organs and implants. The medical
challenge raised by transplant rejection is driving interest in the development
of biomaterials that help prevent biological rejection of transplanted organs.
Other healthcare applications of biomaterials include use in medical devices,
dental restoratives, drug delivery and cosmeceuticals. Major factors spurring
growth in the medical sector include use of collagen in wound dressings and as dermal
fillers in aesthetic procedures, and high prevalence of osteoarthritis. In the
cosmetics industry, growth is driven by aging population, and increased
consumer spending on cosmeceuticals.
The market, in
the coming years, is expected to benefit from the innovative development of new
product solutions. Viscosupplements dominates the
HA-based biomaterials market, supported by the development of novel and
convenient single injection products. Viscosupplement products are used in the
treatment of osteoarthritis of the knee, hip and shoulder. Growing patient
demand for effective treatment options with lower side-effects is encouraging adoption
of HA-based products over other traditional pain relieving methods and
replacement surgeries. Use of HA-based biomaterials in facial aesthetic dermal fillers
is forecast to grow rapidly in developing markets of China, India, and Brazil. Demand for collagen-based dermal
fillers, in comparison, is slowing down as a result of intense competition
from substitutes, including HA-based biomaterials, and Botox which are
perceived to be safer and less allergic. Developments in tissue engineering in
wound care are creating opportunities for biological dressing. Demand, against
this backdrop, is expected to grow strongly for collagen matrix dressings. In
the United States, favorable reimbursement policies are encouraging adoption of
advanced wound care therapies.
Despite the numerous opportunities for growth, the market continues to
face challenges such as inadequate reimbursement for biomaterials. In the
United States, the USFDA categorizes viscosupplements as a device, not a drug.
Medicare reimbursements are available in the country only for hyaluronic
acid-based products for the treatment of knee osteoarthritis, excluding
off-label uses for the treatment of shoulder and hip osteoarthritis. Other
challenges faced by the biomaterials market include high development costs,
lengthy approval procedures, and pricing pressures. In the future, although the role of biomaterials will expand
significantly in medicine and healthcare, non-medical applications will
nevertheless hold attractive opportunities for growth.
As stated by
the new market research report on Collagen and HA-based Biomaterials, the United States represents the largest
market worldwide, followed by Europe and Japan. Asia-Pacific is forecast to
emerge as the fastest growing market with a CAGR of 9.1% over the analysis
period. Growth in the region is led by developing healthcare infrastructure, higher
consumer disposable income, and increased adoption of collagen and HA-based
products.
Major players
covered in the report include Genzyme, Seikagaku, Allergan, Alcon Laboratories
Inc., Anika Therapeutics, Collagen Solutions Plc., Galderma, Genzyme, Fidia, Bausch
& Lomb, Lifecore Biomedical, Teijin Pharma Limited, among others.
Comments
Post a Comment